1. Home
  2. HCAC vs HELP Comparison

HCAC vs HELP Comparison

Compare HCAC & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HCAC

Hall Chadwick Acquisition Corp Class A Ordinary Shares

N/A

Current Price

$9.94

Market Cap

290.5M

ML Signal

N/A

HELP

Cybin Inc. Common Stock

N/A

Current Price

$5.21

Market Cap

249.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HCAC
HELP
Founded
2025
N/A
Country
Singapore
Canada
Employees
N/A
50
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
290.5M
249.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HCAC
HELP
Price
$9.94
$5.21
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$95.00
AVG Volume (30 Days)
206.4K
708.9K
Earning Date
01-01-0001
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.92
$4.29
52 Week High
$10.06
$8.55

Technical Indicators

Market Signals
Indicator
HCAC
HELP
Relative Strength Index (RSI) 31.74 47.91
Support Level N/A $4.40
Resistance Level $9.96 $8.55
Average True Range (ATR) 0.01 0.29
MACD 0.00 0.14
Stochastic Oscillator 25.00 78.45

Price Performance

Historical Comparison
HCAC
HELP

About HCAC Hall Chadwick Acquisition Corp Class A Ordinary Shares

Hall Chadwick Acquisition Corp is a blank check company.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: